Navigation Links
Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
Date:4/26/2011

ing conventional dosing of paclitaxel at 200 mg/m2 every three weeks (conventional treatment Arm A) with paclitaxel blood level testing and subsequent individual dose adjustments (experimental treatment Arm B), with the primary objective to significantly reduce grade 4 neutropenia in patients within treatment Arm B, without adversely affecting chemotherapy efficacy in terms of progression-free survival (PFS) and overall survival (OS).

About non-small cell lung cancer (NSCLC)

Lung cancer is the most common cancer in the world today, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases.  According to the Centers for Disease Control and Prevention (CDC), about 90% of lung cancer deaths in men and almost 80% of lung cancer deaths in women are due to smoking.  Treatment for NSCLC varies depending on the stage of the cancer, though combinations of taxanes are routinely used as part of first-line therapy treatment regimens.  Common side effects of taxanes include polyneuropathy and bone marrow suppression which results in severe neutropenia.

About pharmacokinetic-guided dosing

There is increasing evidence for the relationship between paclitaxel plasma concentrations, drug-associated toxicity, especially neutropenia and clinical outcome.  These data are derived from various pharmacological studies in patients with solid tumors, including lung cancer, ovarian cancer, breast cancer and less frequent cancer types.  The aim of TDM is to decrease toxicity while maintaining or improving treatment efficacy as compared to the standard of care.  Prospective pharmacokinetic studies with dose adjustments are important to evaluate the value of paclitaxel TDM.

About the CESAR Central European Society for Anticancer Drug Research-EWIV  

In the context of the pan-European Early Drug Development Network, CESAR represents the Central European platform for n
'/>"/>

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Symmetry Medical Centralizes Businesses Under CEO
2. Central Texas Hospital Selects eCareSoft EHR Technology
3. FDA Approves Gadavist for Central Nervous System Scans
4. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
5. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
6. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
8. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
10. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
11. Wound Management Technologies Adds Panama to Growing List of Distribution Points in Central America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Cambrex Corporation (NYSE: CBM ) reports results for the ... , Sales increased 18% compared to the first ... driven by Innovator products and Controlled Substances. , EBITDA ... quarter of 2014. , GAAP Diluted EPS from continuing ... year and Adjusted Diluted EPS was $0.29 compared to $0.07 ...
(Date:4/30/2015)... April 30, 2015 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the fourth ... Fourth quarter and fiscal 2015 overview: , ... fourth quarter, up 33% over last year,s comparable quarter, ... , Diluted EPS of $0.50 for the fourth ...
(Date:4/30/2015)... , April 30, 2015  IRIDEX Corporation (NASDAQ: ... its first quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, May 7, ... and other business developments. Interested parties may ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... Calif., Sept. 1, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... that management will present a company overview at Stifel Nicolaus, ... p.m. ET at the Four Seasons Hotel in Boston. ... available on the "Investors & Media" section of the Company,s ...
... Sept. 1, 2011 People seeking support ... prepare to be disappointed – and to make a ... cardiologist, Dr. Carl Lavie, medical director of Cardiac Rehabilitation ... Orleans, LA, "flush-free" niacin may not cause flushing, but ...
Cached Medicine Technology:Leading Expert's Heart Health Advice: Flush Your "Flush-Free" Dietary Supplement Niacin 2Leading Expert's Heart Health Advice: Flush Your "Flush-Free" Dietary Supplement Niacin 3
(Date:5/3/2015)... Boston, MA (PRWEB) May 03, 2015 ... received clearance from the FDA to produce and market ... This device can be used in outpatient settings and ... , The alternate posterior approach has been extensively researched ... a 510k approval to use this approach in conjunction ...
(Date:5/2/2015)... May 02, 2015 Vancouver fencing company, QS ... provide valuable advice to prospective clients related to their questions ... to install railings around their decks and patios. While that ... that pop up once the person rolls up their sleeve ... installing a railing in finding a gate that matches it. ...
(Date:5/2/2015)... Peachtree Audio ” was featured on NewsWatch as part ... and coolest technology products available to consumers. Scott Steinberg, ... the review and shared with viewers how this is ... important part of people’s lives – and as such, ... Peachtree Audio does just that with high-end audio equipment ...
(Date:5/2/2015)... May 02, 2015 With the success that ... is proud to welcome Neida Miranda and Alex Shields to ... Consulting has over 41 years of combined experience working with ... in the dental field for 8 years. She was ... Waco, Texas. Customer service, positive attitude and showing the importance ...
(Date:5/1/2015)... Freeport, ME (PRWEB) May 01, 2015 ... store in Freeport, Maine, reports on a new study ... pain, stiffness, joint swelling and improved physical function as ... people with severe osteoarthritis of the knee. , The ... “ Natural Insights for Well Being® ,” which Royal ...
Breaking Medicine News(10 mins):Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2
... this week by the U.S. Supreme Court will protect the rights of ... LLP . “The Supreme Court’s ruling this week is an important victory ... attorney Robert Kientz. , ... Austin, TX (Vocus) March 6, 2009 -- ...
... but some people don,t realize how precious it really is. 24k gold ... formulas on the market. , ... New York (PRWEB) March 6, 2009 -- While watching ... Gold. It,s common to hear that it has kept a rather high ...
... Diagnosing and treating obstructive sleep apnea may soon ... new research showing that a simplified program using ... positive airway pressure (CPAP) machines to titrate CPAP ... which relies on specialist physicians and sleep studies. ...
... Medical Association (NMA) congratulates the President and his staff ... in today,s forum. The NMA is committed to ... advocacy community, and other stakeholders, to ensure that the ... the President can sign before the Congress adjourns for ...
... of Hispanic health advocates is committed to achieving meaningful ... have work to do to cover the uninsured, improve ... someone has access it is to the type of ... L. Delgado, President and CEO of the National Alliance ...
... Stockholders to Vote the GOLD CardCINCINNATI, March 5 ... announces that RiskMetrics Group,s ISS Governance Services has ... Company,s current Board of Directors and reject all ... and election of replacement Directors, in the Joffe ...
Cached Medicine News:Health News:Supreme Court Ruling is a Victory for Consumers Injured by Dangerous Drugs, Says Hissey Kientz, LLP 2Health News:Supreme Court Ruling is a Victory for Consumers Injured by Dangerous Drugs, Says Hissey Kientz, LLP 3Health News:Gold Not Only Valuable, It's a Healthy Skin Care Ingredient 2Health News:Less costly, more accessible and as effective: Simplified treatment for sleep apnea 2Health News:Less costly, more accessible and as effective: Simplified treatment for sleep apnea 3Health News:Alliance President and CEO Dr. Jane L. Delgado Joins President Obama at White House to Launch Health Reform Agenda 2Health News:Leading Proxy Advisory Firm RiskMetrics Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 2Health News:Leading Proxy Advisory Firm RiskMetrics Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: